1. Home
  2. VSME vs MYNZ Comparison

VSME vs MYNZ Comparison

Compare VSME & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VS Media Holdings Limited

VSME

VS Media Holdings Limited

HOLD

Current Price

$0.08

Market Cap

7.6M

Sector

N/A

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.15

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSME
MYNZ
Founded
2013
2021
Country
Hong Kong
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
VSME
MYNZ
Price
$0.08
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
11.3M
185.2K
Earning Date
04-14-2026
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,483,152.00
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.92
52 Week High
$3.21
$8.20

Technical Indicators

Market Signals
Indicator
VSME
MYNZ
Relative Strength Index (RSI) 25.16 50.40
Support Level $0.07 $1.09
Resistance Level $0.12 $1.29
Average True Range (ATR) 0.01 0.09
MACD 0.03 0.02
Stochastic Oscillator 16.52 59.32

Price Performance

Historical Comparison
VSME
MYNZ

About VSME VS Media Holdings Limited

VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: